News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,408 Results
Type
Article (13725)
Company Profile (256)
Press Release (242427)
Section
Business (79157)
Career Advice (147)
Deals (13164)
Drug Delivery (28)
Drug Development (50148)
Employer Resources (31)
FDA (5635)
Job Trends (5103)
News (143593)
Policy (10010)
Tag
Academia (900)
Africa (145)
Allergies (30)
Alliances (21402)
Alzheimer's disease (686)
Antibody-drug conjugate (ADC) (32)
Approvals (5600)
Arizona (38)
Artificial intelligence (29)
Asia (16642)
Australia (2780)
Bankruptcy (96)
Best Places to Work (4350)
Biotechnology (214)
C2C Services and Suppliers (10603)
California (1232)
Canada (502)
Cancer (307)
Career advice (128)
CAR-T (33)
Cell therapy (95)
China (90)
Clinical research (39052)
Collaboration (86)
Colorado (40)
Compensation (40)
Connecticut (43)
COVID-19 (978)
Cystic fibrosis (58)
Data (230)
Diabetes (38)
Diagnostics (1157)
Earnings (28356)
Employer resources (29)
Europe (35694)
Events (45787)
Executive appointments (99)
FDA (5754)
Florida (123)
Funding (100)
Gene therapy (81)
GLP-1 (263)
Government (1052)
Healthcare (6510)
Hotbed/Location (184111)
Illinois (75)
Indiana (44)
Infectious disease (988)
Inflammatory bowel disease (79)
IPO (7138)
Job creations (856)
Job search strategy (124)
Kansas (52)
Layoffs (177)
Legal (1369)
Lung cancer (71)
Manufacturing (29)
Maryland (189)
Massachusetts (999)
Medical device (2514)
Medtech (2515)
Mergers & acquisitions (6036)
Metabolic disorders (133)
Michigan (38)
Minnesota (65)
Neuroscience (796)
New Jersey (332)
New York (400)
NextGen Class of 2024 (1975)
Non-profit (837)
North Carolina (327)
Northern California (535)
Obesity (76)
Ohio (62)
Opinion (86)
Parkinson's disease (32)
Patents (36)
Pennsylvania (280)
People (24705)
Pharmaceutical (41)
Phase I (13700)
Phase II (18163)
Phase III (11552)
Pipeline (77)
Postmarket research (842)
Preclinical (5767)
Press Release (30)
Radiopharmaceuticals (199)
Rare diseases (102)
Real estate (1405)
Regulatory (8021)
Research institute (928)
South America (206)
Southern California (512)
Startups (1963)
Texas (115)
United States (4715)
Vaccines (133)
Washington State (154)
Weight loss (59)
Date
Today (44)
Last 7 days (364)
Last 30 days (1378)
Last 365 days (21355)
2024 (15136)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
256,408 Results for "vigeo therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, is pleased to announce that a complete response patient (CR) in Glioblastoma (GBM) cohort from first in human study VT1021-01 (NCT03364400) has now completed 3 full years of dosing with VT1021.
July 13, 2023
·
2 min read
Genetown
Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced encouraging new data from its phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma.
May 25, 2023
·
3 min read
Drug Development
Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session
Vigeo Therapeutics today announced new data from its Phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma (rGBM).
June 2, 2023
·
3 min read
Biotech Bay
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven’s troriluzole and Vigeo’s VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).
July 6, 2022
·
8 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society of NeuroOncology’s 2021 Annual Meeting
Vigeo Therapeutics today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with recurrent glioblastoma (rGBM).
November 16, 2021
·
3 min read
Drug Development
Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced completion of the Phase 1/2 dose expansion studies evaluating its lead asset VT1021 in recurrent glioblastoma and pancreatic cancer.
September 21, 2021
·
4 min read
Genetown
Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with pancreatic cancer and recurrent glioblastoma (rGBM).
November 9, 2021
·
4 min read
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Genetown
Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced it will have two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 2021 Annual Meeting, taking place from November 10-14, 2021.
October 1, 2021
·
2 min read
1 of 25,641
Next
